New treatment for alcohol use disorders using ALDH2 inhibitors
ALDH2 inhibitors for the treatment of AUD
['FUNDING_R21'] · UNIVERSITY OF MARYLAND BALTIMORE · NIH-10830460
This study is exploring a new way to help people with alcohol use disorders by focusing on a specific enzyme in the liver, aiming to create treatments that can reduce cravings for alcohol while causing fewer side effects.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MARYLAND BALTIMORE (nih funded) |
| Locations | 1 site (BALTIMORE, UNITED STATES) |
| Trial ID | NIH-10830460 on ClinicalTrials.gov |
What this research studies
This research investigates a novel approach to treating alcohol use disorders (AUDs) by targeting the ALDH2 enzyme, which plays a key role in metabolizing acetaldehyde, a toxic byproduct of alcohol consumption. The study aims to develop and test new small-molecule inhibitors that specifically target the liver, minimizing side effects associated with broader treatments. By synthesizing and evaluating various analogs of a promising compound, YA7068, the researchers hope to find effective therapies that can reduce alcohol-seeking behavior and improve patient outcomes. The research will involve both laboratory and animal testing to validate the effectiveness of these inhibitors.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with alcohol use disorder who may benefit from new therapeutic options.
Not a fit: Patients who do not have alcohol use disorder or those who are not seeking treatment for alcohol-related issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted treatments for individuals struggling with alcohol use disorders.
How similar studies have performed: Previous research has shown promise in targeting metabolic pathways for treating alcohol use disorders, suggesting that this approach could yield significant advancements.
Where this research is happening
BALTIMORE, UNITED STATES
- UNIVERSITY OF MARYLAND BALTIMORE — BALTIMORE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: XUE, FENGTIAN — UNIVERSITY OF MARYLAND BALTIMORE
- Study coordinator: XUE, FENGTIAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.